The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Eisai's 2012 sales performance.
Dependent upon the results of this analysis, Eisai may submit for full approval at some point this year. ... Alzheimer’s disease is a progressive and devastating disease with few treatment options,” said Haruo Naito, chief executive officer at Eisai.
compound.”. In an online statement, Biogen has said that it ‘will continue to advocate for patients and remains committed to research and development, as well as to its collaboration with Eisai,
The crucial study assessed the combination of Lenvima (lenvatinib) – a multiple receptor tyrosine kinase inhibitor administered orally as a pill, discovered by Eisai – with Merck’s anti-PD-1 therapy Keytruda ... advanced endometrial carcinoma,"
Biogen and Eisai have announced plans for a global, phase 3 clinical trial to confirm the long-term clinical benefit of Aduhelm treatment against Alzheimer’s disease. ... Few experts question that Biogen and Eisai’s monoclonal antibody Aduhelm
This week, Eisai and Biogen presented a new sensitivity analysis at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, Massachusetts, based on an open-label extension. ... Eisai and Biogen have also presented some insights around the
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...